As a result, the company expects to resume study enrollment in the coming weeks.
The FDA lifted the clinical hold following its review of results from an in vivo genotoxicity study that it had requested due to the study being conducted with multiple doses in patients.
Viking had planned to conduct this study before Phase 2 but accelerated its execution based on FDA's request.
The results showed no evidence of genotoxicity following exposure to VK0214. The company does not believe that the temporary clinical hold has significantly impacted the long-term development timeline for VK0214.
The Phase 1b study of VK0214 is designed to enroll patients with adrenomyeloneuropathy (AMN), the most common form of X-ALD.
Price Action: VKTX shares traded 2.30% higher at $3.56 on the last check Tuesday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.